Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 16Thyroid Cancer, Papillary 8Adenocarcinoma, Follicular 8Thyroid Nodule 1Thyroid Diseases 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Low Risk Differentiated Thyroid Cancer 1Leukemia, Myelomonocytic, Chronic 1Infertility 1Hyperthyroidism 1Hodgkin Disease 1Head and Neck Neoplasms 1Differentiated Thyroid Cancer 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Thyrotropin Alfa 4donafenib 2Injections 2vandetanib 1surufatinib 1pembrolizumab 1lenvatinib 1apatinib 1anlotinib 1Sorafenib 1Iodine-131 1Everolimus 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Differentiated Thyroid Cancer × Iodine-131 × Clear all
NCT04964284 2023-10-23

Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Unknown
328 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡